Compare AGPU & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGPU | TCRT |
|---|---|---|
| Founded | 2002 | 1998 |
| Country | United States | United States |
| Employees | 24 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9M | 7.7M |
| IPO Year | N/A | 2025 |
| Metric | AGPU | TCRT |
|---|---|---|
| Price | $1.43 | $3.23 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 42.0K | 12.5K |
| Earning Date | 03-27-2026 | 03-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,900,000.00 |
| Revenue This Year | $486.27 | $5,680,500.00 |
| Revenue Next Year | $65.50 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.25 | $1.31 |
| 52 Week High | $9.00 | $5.48 |
| Indicator | AGPU | TCRT |
|---|---|---|
| Relative Strength Index (RSI) | 30.67 | 49.86 |
| Support Level | N/A | $2.91 |
| Resistance Level | $2.83 | $3.73 |
| Average True Range (ATR) | 0.21 | 0.25 |
| MACD | 0.05 | -0.03 |
| Stochastic Oscillator | 20.51 | 25.69 |
Axe Compute Inc functions as an active infrastructure operator. The company intends to expand access to AI compute resources by utilizing the Aethir network, which provides scalable, cost-efficient cloud GPU services for AI, machine learning, gaming, and rendering applications. Through the use of Aethir's decentralized international infrastructure, it aims to provide access to bare-metal GPUs at scale for both emerging and established organizations. It plans to monetize access to the network by serving enterprise customers that require guaranteed capacity, service-level agreements, and a counterparty operating within conventional corporate and regulatory frameworks.
Alaunos Therapeutics Inc is a preclinical stage obesity and metabolic health drug development company that is aiming to develop a small molecule-based drug to treat obesity and other metabolic disorders that have a differentiated profile relative to currently marketed and in development oral and injectable products. The company focuses on evaluating the impact of ALN1001, its primary program, and its derivatives on lipid deposition and gene expression. It aims to develop an oral obesity compound that addresses many of the shortcomings of injectable GLP-1 receptor agonists including preserving lean muscle mass.